磷酸氟达拉滨（NSC 312887）用于晚期宫颈癌患者的II期研究。一项西南肿瘤协作组的研究。
Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer. A Southwest Oncology Group study.
作者信息
Von Hoff D D, Green S, Surwit E A, Hannigan E V, Alberts D S
机构信息
University of Texas Health Science Center, San Antonio 78284-7884.
出版信息
Am J Clin Oncol. 1990 Oct;13(5):433-5. doi: 10.1097/00000421-199010000-00014.
Abstract
Twenty evaluable patients with advanced cervical cancer refractory to one prior chemotherapy regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicities were anemia and leukopenia. Based on this study, fludarabine phosphate does not appear to be an active agent for patients with chemotherapy refractory cervical cancer.
摘要
20例对一种先前化疗方案难治的晚期宫颈癌可评估患者接受了为期5天的磷酸氟达拉滨治疗。未观察到缓解情况。主要毒性为贫血和白细胞减少。基于这项研究，磷酸氟达拉滨对于化疗难治性宫颈癌患者似乎不是一种有效的药物。
Zotero 插件